TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Visual acuity measure BCVA photopic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity measure UCVA photopic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity measure BCVA mesopic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity measure UCVA mesopic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Responders with Improvement in Worst Itch Numeric Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the respiratory pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Specificity of the respiratory pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area Under the Concentration-time Curve to Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of PEC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Neurological status evaluated with the Pediatric Cerebral Performance Category Scale (PCPCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Neurological status evaluated with the modified Rankin Scale (mRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical Laboratory Testing - Iron Panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects achieving a 20% or greater reduction in IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual Irregularities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Anti mullerian Hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Dehydroepiandrosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants with Complete Thrombotic Microangiopathy Response (cTMAr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alanine aminotransferase (ALT) recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Aspartate transaminase (AST) recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Progression to hepatocellular carcinoma (HCC)
Endpoint domain: Mortality/survival
Primary endpoint: Rate of resolution of cervical intraepithelial neoplasia grade 1 (CIN-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of physician-patient relationship
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Numerical rating scale (NRS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Number of participants who filed taxes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants who received the EITC
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in concentrations of biomarkers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Degree of connectivity between brainstem nuclei and brain networks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Colic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average number of cigarettes consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Symptoms of Long COVID-19 Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Body Temperature in Long COVID-19 Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pulse Rate in Long COVID-19 Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Blood Oxygenation in Long COVID-19 Patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the curve from 0 to 24 hours after dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readmission risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SIADH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: SIADH and inflammaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Average Sleep Latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Days per week of cannabis use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change over time in HIV knowledge needed for HIV prevention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change over time in STI knowledge needed for HIV prevention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: seroconversion rate of anti-SARS-CoV-2 IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ability to control the Tele BCI-FES
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants completing each TeleBCI-FES intervention session
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diabetes-Specific Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum tolerated dose (MTD) or maximum administered dose (MAD) of BAY2416964
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Women's Experiences of Vaginal Examinations in Labour Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of positive humoral vaccine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain level using 0-100 Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patient reporting severe pain (VAS 75-100)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: low grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chair stand test duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visceral adipose tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total recovery of radioactivity from urine and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of total radioactive dose in Plasma, Urinary and Fecal Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in mean Continuous Glucose Monitor (CGM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: array characterization metrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of inflammation detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: immune response measured by serum neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of device-related thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of stroke and transient ischemic attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of ultrasound navigation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: App usage (feasibility)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient satisfaction with the gambling app
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Alcoholics drinks consumed per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with a detectable HIV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of retinal breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Distribution of retinal breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Gross Motor Function Measure 88 (D and E dimensions)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Daily Activities Questionnaire (EDAQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short Form-36 (SF-36v1)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Absorbed radiation doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median nerve sensory and motor distal latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain using a visual analogue scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hand grip strength measured by hydraulic hand dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impact of external mechanical compression on overall sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change of muscle tone of the wrist flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Efficacy of Omalizumab treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) from time zero to last quantifiable concentration (AUClast) of osivelotor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) from time zero to extrapolated infinite time (AUCinf) of osivelotor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of osivelotor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women currently using any contraceptives
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of women currently using modern short-term contraceptives
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of women who consumed 100 or more Iron Folic Acid (IFA) tablets during last pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of women who received 4 or more antenatal check-ups during last pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women who received a postnatal check-up within 6 weeks of the delivery from a healthcare provider
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC) of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Follicle stimulating hormone (FSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Luteinizing hormone (LH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Estradiol (E2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Sex hormone binding globulin (SHBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Shape of the hairline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Geometric mean titer (GMT) of antigen 1 antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean increase (GMI) of Antigen 1 antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with antigen 1 seroconversion rate (SCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of Dose Limiting Toxicities (DLTs) in monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Dose Limiting Toxicities (DLTs) in combination therapy
Endpoint domain: Adverse events/effects
Primary endpoint: anxiety disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mindful attention awareness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Brittberg-Peterson functional assessment score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Inhibition zone diameter (mm) for silver nanoparticles against Staphylococcus aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Inhibition zone diameter (mm) for silver nanoparticles against Pseudomonas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Inhibition zone diameter (mm) for copper nanoparticles against Staphylococcus aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Inhibition zone diameter (mm) for copper nanoparticles against Pseudomonas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Persistent confirmed islet autoantibodies or type 1 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mental and physical health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Detection of potential episodes of disconnected consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of potential episodes of connected consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Measures quality of life status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to the First Occurrence of Composite Endpoint of Stroke and Non-central nervous system (CNS) Systemic Embolism
Endpoint domain: Mortality/survival
Primary endpoint: Selective motor control function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: surgical rating scale percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Functional Fitness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: DFU Closure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CMT by OCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S-ROM-Neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative incidence of persistent COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Change in diarrhea duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: compliance to the screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Difference in number of poor mental health days
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in self-ratings with DERS-SF
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in parent-ratings with DERS-SF
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in parental rated Target behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total oxidant and antioxidant plasma capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in total scores of Social Responsiveness Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: AUC max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Peak Nasal Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Median Peak Nasal Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: New Mobility Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average change in luteinizing hormone (LH) pulse amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: UES pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90 day good functional outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Resistivity index of both right and left vertebral arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Arthroscopic tear position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differentiation between benign and malignant lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: The relapse-free period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The need for surgical intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in preoperative anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sandvik urinary incontinence severity test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Pain Perception
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Esthetic Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Device Related or Device Procedure Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Subject incidence of laboratory abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of correct outcome predictions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood oxygen level-dependent (BOLD) responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of periprocedural myocardial injury and infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Percentage Change From Baseline in EASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Total incidence of solicited reactions (systemic and local)
Endpoint domain: Adverse events/effects
Primary endpoint: Need for another chest tube
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 1-year hospital readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Dermoscopic assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in stool microbiota-related metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in blood microbiota-related metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sessile serrated lesion detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change-from-baseline QTc based on the Fridericia correction (ΔΔQTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of participants with best objective response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of Envarsus as indicated by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Influenza vaccination uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Self-efficacy in managing patient-physician interactions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Mean Amplitude of Glycemic Excursion (MAGE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Delay from Initial Orientation Nurse (ION) to initiation of antibiotic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Snoring / Sleep Survey (SSS)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Exclusion Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time required to collect and analyze data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Questionnaire reminders
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Support to complete questionnaires
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Depression severity measured by GDS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinically significant liver fat loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment Success at 4 Weeks Post Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of HLX208
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes